Wnt modulates MCL1 to control cell survival in triple negative breast cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Yang, Lixin ^a   Perez, Aldwin A ^a   Fujie, Sayuri ^a   Warden, Charles ^a   Li, Jie ^a   Wang, Yafan ^a   Yung, Bryan ^a   Chen, Yun Ru ^a   Liu, Xiyong ^a   Zhang, Hang ^b   Zheng, Shu ^b   Liu, Zheng ^a   Ann, David ^a   Yen, Yun ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

MCL1; Triple negative breast cancer (TNBC); WNT catenin pathway; WNT5B

Indexed keywords

CASPASE; LIGAND; MITOCHONDRIAL DNA; MYC PROTEIN; PROTEIN MCL 1; SHORT HAIRPIN RNA; WNT5B PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CELL ASSAY; CELL GROWTH; CELL MIGRATION; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ELECTRON MICROSCOPY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MICROARRAY ANALYSIS; MITOCHONDRION; ONCOGENE MYC; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; WESTERN BLOTTING; WOUND HEALING;

CELL LINE, TUMOR; CELL SURVIVAL; COHORT STUDIES; FEMALE; HUMANS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; SURVIVAL RATE; TRIPLE NEGATIVE BREAST NEOPLASMS; WNT PROTEINS;

EID: 84896737860     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-124     Document Type: Article

References (43)

1. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13(8):2329-2334. 10.1158/1078-0432.CCR-06-1109, 17438091.
2. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007, 608:1-22. 10.1007/978-0-387-74039-3_1, 17993229.
3. Joensuu H, Gligorov J. Adjuvant treatments for triple-negative breast cancers. Ann Oncol 2012, 23(Suppl 6):vi40-vi45.
4. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2011, 9(1):16-32. 10.1038/nrclinonc.2011.177, 22124364.
5. Amir E, Ocana A, Freedman O, Clemons M, Seruga B. Chemotherapy: dose-dense treatment for triple-negative breast cancer. Nat Rev Clin Oncol 2010, 7(2):79-80. 10.1038/nrclinonc.2009.231, 20118978.
6. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer-current status and future directions. Ann Oncol 2009, 20(12):1913-1927. 10.1093/annonc/mdp492, 19901010.
7. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010, 28(7):1145-1153. 10.1200/JCO.2009.22.4725, 2834466, 20100965.
8. DiMeo TA, Anderson K, Phadke P, Fan C, Perou CM, Naber S, Kuperwasser C. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res 2009, 69(13):5364-5373. 10.1158/0008-5472.CAN-08-4135, 2782448, 19549913.
9. Lindvall C, Bu W, Williams BO, Li Y. Wnt signaling, stem cells, and the cellular origin of breast cancer. Stem Cell Rev 2007, 3(2):157-168. 10.1007/s12015-007-0025-3, 17873348.
10. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486(7403):395-399. 3863681, 22495314.
11. Yang L, Wu X, Wang Y, Zhang K, Wu J, Yuan YC, Deng X, Chen L, Kim CC, Lau S, et al. FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene 2011, 30(43):4437-4446. 10.1038/onc.2011.145, 21532620.
12. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127(3):469-480. 10.1016/j.cell.2006.10.018, 17081971.
13. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009, 17(1):9-26. 10.1016/j.devcel.2009.06.016, 2861485, 19619488.
14. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005, 434(7035):843-850. 10.1038/nature03319, 15829953.
15. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997, 275(5307):1784-1787. 10.1126/science.275.5307.1784, 9065401.
16. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275(5307):1787-1790. 10.1126/science.275.5307.1787, 9065402.
17. Kikuchi A, Yamamoto H, Sato A. Selective activation mechanisms of Wnt signaling pathways. Trends Cell Biol 2009, 19(3):119-129. 10.1016/j.tcb.2009.01.003, 19208479.
18. van Amerongen R, Nusse R. Towards an integrated view of Wnt signaling in development. Development 2009, 136(19):3205-3214. 10.1242/dev.033910, 19736321.
19. Mori H, Prestwich TC, Reid MA, Longo KA, Gerin I, Cawthorn WP, Susulic VS, Krishnan V, Greenfield A, Macdougald OA. Secreted frizzled-related protein 5 suppresses adipocyte mitochondrial metabolism through WNT inhibition. J Clin Invest 2012, 122(7):2405-2416. 10.1172/JCI63604, 3386832, 22728933.
20. Chacinska A, Koehler CM, Milenkovic D, Lithgow T, Pfanner N. Importing mitochondrial proteins: machineries and mechanisms. Cell 2009, 138(4):628-644. 10.1016/j.cell.2009.08.005, 19703392.
21. Galluzzi L, Kepp O, Kroemer G. Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol 2012, 13(12):780-788. 10.1038/nrm3479, 23175281.
22. Wallace DC. Mitochondria and cancer. Nat Rev Cancer 2012, 12(10):685-698. 10.1038/nrc3365, 23001348.
23. R Development Core Team R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing 2013, R Development Core Team.
24. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo W-L, Lapuk A, Neve RM, Qian Z, Ryder T, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006, 10(6):529-541. 10.1016/j.ccr.2006.10.009, 17157792.
25. The Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490(7418):61-70. 10.1038/nature11412, 3465532, 23000897, The Cancer Genome Atlas Network.
26. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies MS, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG Multicenter Independent Validation Series. Clin Cancer Res 2007, 13(11):3207-3214. 10.1158/1078-0432.CCR-06-2765, 17545524.
27. Wang Y, Klijn JGM, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365(9460):671-679. 10.1016/S0140-6736(05)17947-1, 15721472.
28. Bozzola JJ. Conventional specimen preparation techniques for transmission electron microscopy of cultured cells. Meth Mol Biol (Clifton, NJ) 2007, 369:1-18.
29. Lin TC, Chen YR, Kensicki E, Li AY, Kong M, Li Y, Mohney RP, Shen HM, Stiles B, Mizushima N, et al. Autophagy: resetting glutamine-dependent metabolism and oxygen consumption. Autophagy 2012, 8(10):1477-1493. 10.4161/auto.21228, 3679231, 22906967.
30. Mitra K, Wunder C, Roysam B, Lin G, Lippincott-Schwartz J. A hyperfused mitochondrial state achieved at G1-S regulates cyclin E buildup and entry into S phase. Proc Natl Acad Sci U S A 2009, 106(29):11960-11965. 10.1073/pnas.0904875106, 2710990, 19617534.
31. Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M, Temirov J, Cleland MM, Pelletier S, Schuetz JD, et al. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol 2012, 14(6):575-583. 10.1038/ncb2488, 3401947, 22544066.
32. Labisso WL, Wirth M, Stojanovic N, Stauber RH, Schnieke A, Schmid RM, Kramer OH, Saur D, Schneider G. MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors. Cell Cycle 2012, 11(8):1593-1602. 10.4161/cc.20008, 22456335.
33. Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, van Oers MH, Lokhorst HM, Bloem AC, Clevers H, Nusse R, et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A 2004, 101(16):6122-6127. 10.1073/pnas.0305855101, 395933, 15067127.
34. Verras M, Brown J, Li X, Nusse R, Sun Z. Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells. Cancer Res 2004, 64(24):8860-8866. 10.1158/0008-5472.CAN-04-2370, 15604245.
35. Chien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, Rothberg BG, Berger AJ, Major MB, Hwang ST, Rimm DL, Moon RT. Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A 2009, 106(4):1193-1198. 10.1073/pnas.0811902106, 2626610, 19144919.
36. Yoon JC, Ng A, Kim BH, Bianco A, Xavier RJ, Elledge SJ. Wnt signaling regulates mitochondrial physiology and insulin sensitivity. Genes Dev 2010, 24(14):1507-1518. 10.1101/gad.1924910, 2904941, 20634317.
37. Lehwald N, Tao GZ, Jang KY, Papandreou I, Liu B, Liu B, Pysz MA, Willmann JK, Knoefel WT, Denko NC, et al. beta-Catenin regulates hepatic mitochondrial function and energy balance in mice. Gastroenterology 2012, 143(3):754-764. 10.1053/j.gastro.2012.05.048, 22684045.
38. Ertel F, Nguyen M, Roulston A, Shore GC. Programming cancer cells for high expression levels of Mcl1. EMBO Rep 2013, 14(4):328-336. 10.1038/embor.2013.20, 23478333.
39. Tai WT, Shiau CW, Chen HL, Liu CY, Lin CS, Cheng AL, Chen PJ, Chen KF. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. Cell Death Dis 2013, 4:e485. 10.1038/cddis.2013.18, 3734819, 23392173.
40. Wei G, Margolin AA, Haery L, Brown E, Cucolo L, Julian B, Shehata S, Kung AL, Beroukhim R, Golub TR. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell 2012, 21(4):547-562. 10.1016/j.ccr.2012.02.028, 3685408, 22516262.
41. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, Maecker H, O'Rourke K, Bazan F, Eastham-Anderson J, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010, 463(7277):103-107. 10.1038/nature08646, 20023629.
42. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463(7283):899-905. 10.1038/nature08822, 2826709, 20164920.
43. Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med 2012, 209(4):679-696. 10.1084/jem.20111512, 3328367, 22430491.